Question 1: How does this genetic variant affect the efficacy and/or toxicity of a drug or drugs?
Question 2: Do you see such an effect in specific patient populations?
Question 3: Describe the clinical relevance of the genetic variant and affected drug therapy.
Question 4: When considering drug therapy with the affected drug(s), is genetic testing for this association available, required, or covered by payors?
Question 5: What else did you learn about this genetic variant that you found interesting?